Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2021 results.

What's in the Cards for Bristol-Myers (BMY) Q1 Earnings?

AbbVie

Roche Holding AG

European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Roche Holdings AG's (OTCMKTS: RHHBY) Enspryng, AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax), and Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo Plus Yervoy and Onureg. The final decision is expected to be delivered during the first half of 2021.

Roche, AbbVie, Bristol-Myers Are Latest To Win European Medicines Agency's CHMP Positive Opinion

Bristol-Myers Squibb Co (NYSE: BMY) has announced new data from its two Phase 3 trials POETYK PSO-1 and POETYK PSO-2 for deucravacitinib, its oral, selective TYK2 inhibitor for moderate to severe plaque psoriasis. Data were presented at the 2021 American Academy of Dermatology Virtual Meeting Experience.

Bristol Myers' Psoriasis Med Deucravacitinib Superior To Amgen's Otezla, New Data Shows

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AADVMX2021--Bristol Myers Squibb Presents Positive Data at AAD

Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AML--BMS Receives Positive CHMP Opinion for Onureg® (azacitidine tablets;CC-486) as Frontline Oral Maintenance Therapy forAdults w AML in First Remission

Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo + Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma

Amgen

Regeneron Pharmaceuticals

Replimune Group Inc

Sanofi

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Analysts See Plenty of Upside for Replimune

Is (BMY) Outperforming Other Medical Stocks This Year?

Is Bristol Myers Squibb (BMY) Stock Outpacing Its Medical Peers This Year?

This undervalued pharmaceutical is a great buy in 2021.

Why Bristol Myers Squibb Deserves a Place in Your Portfolio

Bristol-Myers Squibb Co (NYSE: BMY) continues to scale its CAR-T operations with the latest move to open its first cell manufacturing site in Europe and fifth worldwide. BMY is set to build a new cell therapy site in Leiden, the Netherlands.

Bristol Myers To Build First Cell Therapy Factory In Europe

Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.

Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--US FDA Approves Opdivo in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer....

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma.

The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.

Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Opdivo--BMS Receives EC Approval for Opdivo® (nivolumab) in Comb w Cabometyx® (cabozantinib) as First-Line Treatment for Patients w Advanced Renal Cell Carcin

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

WALTHAM, Mass.--(BUSINESS WIRE)-- #Dermatology--Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company, today announced two new appointments to its leadership team.

Pyramid Biosciences Announces Leadership Team Expansion

Merck

See why the world's most acclaimed value investor is investing in these three stocks.

Follow Warren Buffett Into These 3 Pharma Companies

Key recent clinical pipeline developments have prompted an analyst at Truist Securities to turn bullish on pharma giant Bristol-Myers Squibb Company (NYSE: BMY). The Bristol-Myers Squibb Analyst: Gregg Gilbert upgraded Bristol-Myers Squibb from Hold to Buy and increased the price target from $66 to $74.

Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline

Bristol Myers Squibb was upgraded on Tuesday. An analyst says the company's drug pipeline is more valuable than investors appreciate.

Buy Bristol Myers, Analyst Says. It Isn't Getting Enough Credit for Its Drug Pipeline.

Portfolio value is up 10.25% for Q1 with 6.38% coming during March madness alone. Dividend portfolio yield is 4.3% with 45 March payers bringing in 3.1% more for Q1 than Q4 2020 and 4% more than for December Q4 2020 alone.

Rose 95 Stock Portfolio March Madness Q1 Update Including Cost/Share And Purchase Evaluation List

The shares of biopharmaceutical name Bristol-Myers Squibb Co (NYSE:BMY) are up 0.6% at $63.07 in pre-market trading, after Truist Securities upgraded the stock to "buy" from hold," with a price-target hike to $74 from $66.

Biopharmaceutical Stock Flat Despite Upgrade to "Buy"

Bristol Myers Squibb (BMY) announces positive results from a late-stage study evaluating Opdivo plus chemotherapy for resectable NSCLC.

Bristol Myers' (BMY) Opdivo Combo Encouraging in NSCLC study

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AACR21--Neoadjuvant Opdivo + Chemotherapy Significantly Improves Pathologic Complete Response in Patients w/ Resectable NSCLC in Phase 3 CheckMate -816 Trial

Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

Bristol Myers (BMY) announces encouraging data from the late-stage study evaluating Opdivo plus chemotherapy and Opdivo plus Yervoy in ESCC study.

Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study

Bristol Myers Squibb topped fourth-quarter expectations in February and cancer drug Opdivo returned to growth. But BMY stock floundered following the report.

Is Bristol Myers Stock A Buy As Opdivo Faces An FDA Hurdle In April?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Announces Opdivo plus Chemotherapy and Opdivo plus Yervoy Demonstrate Superior Survival Benefit Compared to Chemotherapy.....

CORRECTING and REPLACING Bristol Myers Squibb Announces Opdivo (nivolumab) plus Chemotherapy and Opdivo plus Yervoy (ipilimumab) Demonstrate Superior Survival Benefit Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal.

News for Bristol-Myers Stock (BMY)